nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefadroxil—Blood bilirubin increased—Vandetanib—thyroid cancer	0.0298	0.0298	CcSEcCtD
Cefadroxil—Creatinine increased—Vandetanib—thyroid cancer	0.0296	0.0296	CcSEcCtD
Cefadroxil—Blood bilirubin increased—Sorafenib—thyroid cancer	0.0201	0.0201	CcSEcCtD
Cefadroxil—Blood creatinine increased—Vandetanib—thyroid cancer	0.0191	0.0191	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.018	0.018	CcSEcCtD
Cefadroxil—Prothrombin level increased—Epirubicin—thyroid cancer	0.0171	0.0171	CcSEcCtD
Cefadroxil—Neutropenia—Vandetanib—thyroid cancer	0.0165	0.0165	CcSEcCtD
Cefadroxil—Prothrombin level increased—Doxorubicin—thyroid cancer	0.0158	0.0158	CcSEcCtD
Cefadroxil—Hepatic function abnormal—Sorafenib—thyroid cancer	0.0158	0.0158	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.0156	0.0156	CcSEcCtD
Cefadroxil—Hepatic failure—Sorafenib—thyroid cancer	0.0153	0.0153	CcSEcCtD
Cefadroxil—Haemoglobin—Vandetanib—thyroid cancer	0.0142	0.0142	CcSEcCtD
Cefadroxil—Haemorrhage—Vandetanib—thyroid cancer	0.0141	0.0141	CcSEcCtD
Cefadroxil—Lactic dehydrogenase activity increased—Epirubicin—thyroid cancer	0.0137	0.0137	CcSEcCtD
Cefadroxil—Erythema multiforme—Vandetanib—thyroid cancer	0.0134	0.0134	CcSEcCtD
Cefadroxil—Lactic dehydrogenase activity increased—Doxorubicin—thyroid cancer	0.0127	0.0127	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.0124	0.0124	CcSEcCtD
Cefadroxil—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.0124	0.0124	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.0122	0.0122	CcSEcCtD
Cefadroxil—Blood lactate dehydrogenase increased—Epirubicin—thyroid cancer	0.0121	0.0121	CcSEcCtD
Cefadroxil—Muscle spasms—Vandetanib—thyroid cancer	0.0118	0.0118	CcSEcCtD
Cefadroxil—Blood lactate dehydrogenase increased—Doxorubicin—thyroid cancer	0.0112	0.0112	CcSEcCtD
Cefadroxil—Neutropenia—Sorafenib—thyroid cancer	0.0111	0.0111	CcSEcCtD
Cefadroxil—Convulsion—Vandetanib—thyroid cancer	0.0107	0.0107	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.0105	0.0105	CcSEcCtD
Cefadroxil—Arthralgia—Vandetanib—thyroid cancer	0.0105	0.0105	CcSEcCtD
Cefadroxil—Thrombocytopenia—Vandetanib—thyroid cancer	0.00983	0.00983	CcSEcCtD
Cefadroxil—Haemoglobin—Sorafenib—thyroid cancer	0.00959	0.00959	CcSEcCtD
Cefadroxil—Haemorrhage—Sorafenib—thyroid cancer	0.00954	0.00954	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00915	0.00915	CcSEcCtD
Cefadroxil—Erythema multiforme—Sorafenib—thyroid cancer	0.00902	0.00902	CcSEcCtD
Cefadroxil—Dyspepsia—Vandetanib—thyroid cancer	0.00884	0.00884	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00867	0.00867	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00821	0.00821	CcSEcCtD
Cefadroxil—Muscle spasms—Sorafenib—thyroid cancer	0.00798	0.00798	CcSEcCtD
Cefadroxil—Abdominal pain—Vandetanib—thyroid cancer	0.00794	0.00794	CcSEcCtD
Cefadroxil—Body temperature increased—Vandetanib—thyroid cancer	0.00794	0.00794	CcSEcCtD
Cefadroxil—Angioedema—Sorafenib—thyroid cancer	0.00759	0.00759	CcSEcCtD
Cefadroxil—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00742	0.00742	CcSEcCtD
Cefadroxil—Creatinine increased—Epirubicin—thyroid cancer	0.00737	0.00737	CcSEcCtD
Cefadroxil—Asthenia—Vandetanib—thyroid cancer	0.00721	0.00721	CcSEcCtD
Cefadroxil—Pruritus—Vandetanib—thyroid cancer	0.00711	0.00711	CcSEcCtD
Cefadroxil—Arthralgia—Sorafenib—thyroid cancer	0.00707	0.00707	CcSEcCtD
Cefadroxil—Vaginal inflammation—Epirubicin—thyroid cancer	0.00702	0.00702	CcSEcCtD
Cefadroxil—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.00702	0.00702	CcSEcCtD
Cefadroxil—Diarrhoea—Vandetanib—thyroid cancer	0.00687	0.00687	CcSEcCtD
Cefadroxil—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00687	0.00687	CcSEcCtD
Cefadroxil—Creatinine increased—Doxorubicin—thyroid cancer	0.00682	0.00682	CcSEcCtD
Cefadroxil—Anaphylactic shock—Sorafenib—thyroid cancer	0.00678	0.00678	CcSEcCtD
Cefadroxil—Dizziness—Vandetanib—thyroid cancer	0.00664	0.00664	CcSEcCtD
Cefadroxil—Thrombocytopenia—Sorafenib—thyroid cancer	0.00663	0.00663	CcSEcCtD
Cefadroxil—Vaginal infection—Epirubicin—thyroid cancer	0.00663	0.00663	CcSEcCtD
Cefadroxil—Blood urea increased—Epirubicin—thyroid cancer	0.00663	0.00663	CcSEcCtD
Cefadroxil—Aplastic anaemia—Epirubicin—thyroid cancer	0.00659	0.00659	CcSEcCtD
Cefadroxil—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.00649	0.00649	CcSEcCtD
Cefadroxil—Vaginal inflammation—Doxorubicin—thyroid cancer	0.00649	0.00649	CcSEcCtD
Cefadroxil—Vomiting—Vandetanib—thyroid cancer	0.00639	0.00639	CcSEcCtD
Cefadroxil—Rash—Vandetanib—thyroid cancer	0.00633	0.00633	CcSEcCtD
Cefadroxil—Dermatitis—Vandetanib—thyroid cancer	0.00633	0.00633	CcSEcCtD
Cefadroxil—Headache—Vandetanib—thyroid cancer	0.00629	0.00629	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00617	0.00617	CcSEcCtD
Cefadroxil—Blood urea increased—Doxorubicin—thyroid cancer	0.00613	0.00613	CcSEcCtD
Cefadroxil—Vaginal infection—Doxorubicin—thyroid cancer	0.00613	0.00613	CcSEcCtD
Cefadroxil—Aplastic anaemia—Doxorubicin—thyroid cancer	0.0061	0.0061	CcSEcCtD
Cefadroxil—Nausea—Vandetanib—thyroid cancer	0.00597	0.00597	CcSEcCtD
Cefadroxil—Dyspepsia—Sorafenib—thyroid cancer	0.00596	0.00596	CcSEcCtD
Cefadroxil—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00586	0.00586	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00585	0.00585	CcSEcCtD
Cefadroxil—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00583	0.00583	CcSEcCtD
Cefadroxil—Hepatic failure—Epirubicin—thyroid cancer	0.00567	0.00567	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00554	0.00554	CcSEcCtD
Cefadroxil—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.00542	0.00542	CcSEcCtD
Cefadroxil—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00539	0.00539	CcSEcCtD
Cefadroxil—Urticaria—Sorafenib—thyroid cancer	0.00538	0.00538	CcSEcCtD
Cefadroxil—Abdominal pain—Sorafenib—thyroid cancer	0.00536	0.00536	CcSEcCtD
Cefadroxil—Body temperature increased—Sorafenib—thyroid cancer	0.00536	0.00536	CcSEcCtD
Cefadroxil—Hepatic failure—Doxorubicin—thyroid cancer	0.00525	0.00525	CcSEcCtD
Cefadroxil—Hypersensitivity—Sorafenib—thyroid cancer	0.00499	0.00499	CcSEcCtD
Cefadroxil—Asthenia—Sorafenib—thyroid cancer	0.00486	0.00486	CcSEcCtD
Cefadroxil—Pruritus—Sorafenib—thyroid cancer	0.00479	0.00479	CcSEcCtD
Cefadroxil—Blood creatinine increased—Epirubicin—thyroid cancer	0.00477	0.00477	CcSEcCtD
Cefadroxil—Diarrhoea—Sorafenib—thyroid cancer	0.00464	0.00464	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00459	0.00459	CcSEcCtD
Cefadroxil—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00459	0.00459	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00449	0.00449	CcSEcCtD
Cefadroxil—Dizziness—Sorafenib—thyroid cancer	0.00448	0.00448	CcSEcCtD
Cefadroxil—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00442	0.00442	CcSEcCtD
Cefadroxil—Eosinophilia—Epirubicin—thyroid cancer	0.00436	0.00436	CcSEcCtD
Cefadroxil—Vomiting—Sorafenib—thyroid cancer	0.00431	0.00431	CcSEcCtD
Cefadroxil—Rash—Sorafenib—thyroid cancer	0.00427	0.00427	CcSEcCtD
Cefadroxil—Dermatitis—Sorafenib—thyroid cancer	0.00427	0.00427	CcSEcCtD
Cefadroxil—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00425	0.00425	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00425	0.00425	CcSEcCtD
Cefadroxil—Headache—Sorafenib—thyroid cancer	0.00424	0.00424	CcSEcCtD
Cefadroxil—Pancytopenia—Epirubicin—thyroid cancer	0.00418	0.00418	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00416	0.00416	CcSEcCtD
Cefadroxil—Neutropenia—Epirubicin—thyroid cancer	0.00412	0.00412	CcSEcCtD
Cefadroxil—Eosinophilia—Doxorubicin—thyroid cancer	0.00403	0.00403	CcSEcCtD
Cefadroxil—Nausea—Sorafenib—thyroid cancer	0.00402	0.00402	CcSEcCtD
Cefadroxil—Drowsiness—Epirubicin—thyroid cancer	0.00393	0.00393	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00389	0.00389	CcSEcCtD
Cefadroxil—Pancytopenia—Doxorubicin—thyroid cancer	0.00387	0.00387	CcSEcCtD
Cefadroxil—Neutropenia—Doxorubicin—thyroid cancer	0.00381	0.00381	CcSEcCtD
Cefadroxil—Agranulocytosis—Epirubicin—thyroid cancer	0.00366	0.00366	CcSEcCtD
Cefadroxil—Drowsiness—Doxorubicin—thyroid cancer	0.00363	0.00363	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.0036	0.0036	CcSEcCtD
Cefadroxil—Haemoglobin—Epirubicin—thyroid cancer	0.00354	0.00354	CcSEcCtD
Cefadroxil—Haemorrhage—Epirubicin—thyroid cancer	0.00352	0.00352	CcSEcCtD
Cefadroxil—Agranulocytosis—Doxorubicin—thyroid cancer	0.00339	0.00339	CcSEcCtD
Cefadroxil—Erythema multiforme—Epirubicin—thyroid cancer	0.00333	0.00333	CcSEcCtD
Cefadroxil—Haemoglobin—Doxorubicin—thyroid cancer	0.00328	0.00328	CcSEcCtD
Cefadroxil—Haemorrhage—Doxorubicin—thyroid cancer	0.00326	0.00326	CcSEcCtD
Cefadroxil—Erythema multiforme—Doxorubicin—thyroid cancer	0.00308	0.00308	CcSEcCtD
Cefadroxil—Tension—Epirubicin—thyroid cancer	0.00301	0.00301	CcSEcCtD
Cefadroxil—Nervousness—Epirubicin—thyroid cancer	0.00298	0.00298	CcSEcCtD
Cefadroxil—Muscle spasms—Epirubicin—thyroid cancer	0.00295	0.00295	CcSEcCtD
Cefadroxil—Tension—Doxorubicin—thyroid cancer	0.00279	0.00279	CcSEcCtD
Cefadroxil—Nervousness—Doxorubicin—thyroid cancer	0.00276	0.00276	CcSEcCtD
Cefadroxil—Vertigo—Epirubicin—thyroid cancer	0.00276	0.00276	CcSEcCtD
Cefadroxil—Muscle spasms—Doxorubicin—thyroid cancer	0.00273	0.00273	CcSEcCtD
Cefadroxil—Convulsion—Epirubicin—thyroid cancer	0.00266	0.00266	CcSEcCtD
Cefadroxil—Arthralgia—Epirubicin—thyroid cancer	0.00261	0.00261	CcSEcCtD
Cefadroxil—Vertigo—Doxorubicin—thyroid cancer	0.00255	0.00255	CcSEcCtD
Cefadroxil—Anaphylactic shock—Epirubicin—thyroid cancer	0.0025	0.0025	CcSEcCtD
Cefadroxil—Convulsion—Doxorubicin—thyroid cancer	0.00246	0.00246	CcSEcCtD
Cefadroxil—Thrombocytopenia—Epirubicin—thyroid cancer	0.00245	0.00245	CcSEcCtD
Cefadroxil—Arthralgia—Doxorubicin—thyroid cancer	0.00242	0.00242	CcSEcCtD
Cefadroxil—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00232	0.00232	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00228	0.00228	CcSEcCtD
Cefadroxil—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00227	0.00227	CcSEcCtD
Cefadroxil—Somnolence—Epirubicin—thyroid cancer	0.00223	0.00223	CcSEcCtD
Cefadroxil—Dyspepsia—Epirubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00216	0.00216	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00211	0.00211	CcSEcCtD
Cefadroxil—Somnolence—Doxorubicin—thyroid cancer	0.00206	0.00206	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00205	0.00205	CcSEcCtD
Cefadroxil—Dyspepsia—Doxorubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.002	0.002	CcSEcCtD
Cefadroxil—Urticaria—Epirubicin—thyroid cancer	0.00199	0.00199	CcSEcCtD
Cefadroxil—Abdominal pain—Epirubicin—thyroid cancer	0.00198	0.00198	CcSEcCtD
Cefadroxil—Body temperature increased—Epirubicin—thyroid cancer	0.00198	0.00198	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00189	0.00189	CcSEcCtD
Cefadroxil—Hypersensitivity—Epirubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Cefadroxil—Urticaria—Doxorubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Cefadroxil—Abdominal pain—Doxorubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Cefadroxil—Body temperature increased—Doxorubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Cefadroxil—Asthenia—Epirubicin—thyroid cancer	0.0018	0.0018	CcSEcCtD
Cefadroxil—Pruritus—Epirubicin—thyroid cancer	0.00177	0.00177	CcSEcCtD
Cefadroxil—Diarrhoea—Epirubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Cefadroxil—Hypersensitivity—Doxorubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Cefadroxil—Asthenia—Doxorubicin—thyroid cancer	0.00166	0.00166	CcSEcCtD
Cefadroxil—Dizziness—Epirubicin—thyroid cancer	0.00166	0.00166	CcSEcCtD
Cefadroxil—Pruritus—Doxorubicin—thyroid cancer	0.00164	0.00164	CcSEcCtD
Cefadroxil—Vomiting—Epirubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Cefadroxil—Diarrhoea—Doxorubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Cefadroxil—Rash—Epirubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Cefadroxil—Dermatitis—Epirubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Cefadroxil—Headache—Epirubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Cefadroxil—Dizziness—Doxorubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Cefadroxil—Nausea—Epirubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Cefadroxil—Vomiting—Doxorubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Cefadroxil—Rash—Doxorubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Cefadroxil—Dermatitis—Doxorubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Cefadroxil—Headache—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Cefadroxil—Nausea—Doxorubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
